The DoD FY24 Vision Research Program (VRP) Clinical Trial Award (CTA) is designed to fund early-phase clinical trials that address eye injuries and visual dysfunction related to military service. The award, administered by the Department of the Army’s US Army Medical Research Acquisition Activity (USAMRAA), supports trials testing new drugs, devices, clinical guidelines, or emerging technologies. Only projects meeting the federal definition of a clinical trial, which assesses the safety, effectiveness, or efficacy of an intervention, are eligible for this award.

Applicants must demonstrate regulatory compliance if the trial involves investigational drugs or devices. For drugs, an Investigational New Drug (IND) application, if required, must be filed by the application deadline, and regulatory approval to proceed must be secured by March 1, 2025. For devices, an Investigational Device Exemption (IDE), if required, must follow a similar timeline. Documentation showing readiness to proceed with the trial must be submitted as part of the application, with the clinical trial expected to start within six months of the award date.

The estimated program funding is $2.56 million, with one award expected. Applications are due by November 12, 2024, and applicants should consult additional guidance on regulatory requirements. For assistance, applicants may contact the CDMRP Help Desk.